Summary & Overview
HCPCS Q4082: Unclassified Part B Drug or Biological (CAP)
HCPCS Level II code Q4082 designates a Part B-covered drug or biological that is "not otherwise classified" and is procured through the Competitive Acquisition Program (CAP). Nationally, such unclassified Part B drugs are important for capturing billing when a specific HCPCS descriptor does not exist, ensuring providers can submit claims for otherwise unlisted therapeutics administered in outpatient settings. The code matters for accurate reimbursement, inventory management, and program compliance under Medicare Part B procurement pathways.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical and billing context, expected sites of service, and common claim scenarios. The publication outlines what to look for in documentation, typical use cases for CAP-procured agents, and how this unclassified code fits into Part B outpatient drug workflows. It also summarizes available benchmarks and policy considerations where applicable. Data not available in the input is noted where relevant.
Billing Code Overview
HCPCS Level II code Q4082 is defined as Drug or biological, not otherwise classified, Part B drug Competitive Acquisition Program (CAP). This code represents a Part B-covered pharmaceutical or biological product that does not have a specific HCPCS Level II descriptor and is procured through the Competitive Acquisition Program (CAP) mechanism.
-
Service type: Outpatient/infused or injected pharmaceutical administration under Part B coverage
-
Typical site of service: Hospital outpatient departments, physician offices, and other outpatient infusion settings where Part B drugs are furnished and billed under CAP
Clinical & Coding Specifications
Clinical Context
A typical patient receiving a Part B competitive acquisition program (CAP) drug coded as Q4082 is an adult outpatient with a chronic or complex medical condition requiring a specialty or non-routine biologic or drug not otherwise classified under standard HCPCS listings. The patient commonly presents to an oncology infusion center, hematology/oncology clinic, rheumatology clinic, or an outpatient hospital-based infusion suite for drug administration under Medicare Part B coverage. Clinical workflow: the prescribing clinician documents medical necessity and treatment plan in the chart, orders the CAP drug through the facility’s pharmacy or CAP vendor, verifies coverage and benefit assignment with the patient’s Part B or supplemental payer, schedules the infusion or injection encounter, and delivers the dose per protocol. The facility documents drug name as a Q4082 billed line item, attaches appropriate diagnosis codes to justify use, and appends relevant modifiers for unusual circumstances (for example, increased complexity, same-day unrelated procedures, or performance by a non-physician practitioner). Typical supportive services performed during the encounter include nursing assessment, intravenous access, infusion monitoring, and post-infusion observation. Common payors for prior authorization and claims adjudication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|